Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pexa-Vec followed by Sorafenib vs Sorafenib in Advanced HCC
NCT02562755Phase 3Completed
- Sponsor
- SillaJen
- Start
- Oct 2015
- Primary completion
- Jul 2020
- Modality
- Oncolytic Viruses
- Countries
- 16
01
Overview
A Phase 3 trial of pexastimogene devacirepvec in hepatocellular carcinoma (HCC), sponsored by SillaJen. Started Oct 2015; status: completed.
02
Drugs
pexastimogene devacirepvec
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02562755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02562755.